Prostatic Neoplasms Clinical Trials

22 studies are recruiting for prostatic neoplasms in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

   Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of p…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05616650 on ClinicalTrials.gov

2. A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

   The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agen…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of Arizona Cancer Center - North Campus ( Site 0073), Tucson, Arizona

   Locations

   330 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06136650 on ClinicalTrials.gov

3. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona - Phoenix ( Site 0044), Phoenix, Arizona

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

4. Collection of Blood From Patients With Prostate Cancer

   Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although ever…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00923221 on ClinicalTrials.gov

5. Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

   Background: - Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery f…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01834001 on ClinicalTrials.gov

6. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama Birmingham Hospital, Birmingham, Alabama

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

7. Men at High Genetic Risk for Prostate Cancer

   Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at highe…

   Stage

   Not phased

   Ages

   30 to 75

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03805919 on ClinicalTrials.gov

8. Prostate Active Surveillance Study

   The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This …

   Stage

   Not phased

   Ages

   21 and older

   Site

   Veterans Affairs San Francisco Health Care System, San Francisco, California

   Locations

   11 in total

   Run by

   University of Washington

   See if you can join NCT00756665 on ClinicalTrials.gov

9. A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

   The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose [RP2D]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prost…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists & Research Institute, Sarasota, Florida

   Locations

   3 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07746713 on ClinicalTrials.gov

10. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Anschutz Medical Campus, Aurora, Colorado

    Locations

    19 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT06095089 on ClinicalTrials.gov

11. A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

    The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Sarasota, Florida

    Locations

    6 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07082920 on ClinicalTrials.gov

12. A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

    The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Sarasota, Florida

    Locations

    5 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07319871 on ClinicalTrials.gov

13. A Study of DM002 in Patients With Advanced Solid Tumors

    The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Francisco Cancer Center, San Francisco, California

    Locations

    7 in total

    Run by

    Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

    See if you can join NCT06751329 on ClinicalTrials.gov

14. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

    The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Los Angeles, Los Angeles, California

    Locations

    10 in total

    Run by

    Flare Therapeutics Inc.

    See if you can join NCT07719361 on ClinicalTrials.gov

15. RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

    This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT05765500 on ClinicalTrials.gov

16. Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

    The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance. The name of the study intervention involved in th…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Locations

    4 in total

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT05918263 on ClinicalTrials.gov

17. A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

    Prostate cancer is the most common non-skin cancer among men in the United States. For some men, the cancer has already spread to other parts of the body at the time of diagnosis; this is called metastatic hormone-sensitive prostate cancer (mHSPC). Treatment for mHSPC has advanced significantly, wi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland, Ohio

    Run by

    Bayer

    See if you can join NCT07406282 on ClinicalTrials.gov

18. Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

    To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Biogenix Molecular LLC, Miami, Florida

    Locations

    21 in total

    Run by

    Blue Earth Therapeutics Ltd

    See if you can join NCT05413850 on ClinicalTrials.gov

19. Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

    This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with active surveillance. The study aims to determine wheth…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT07285057 on ClinicalTrials.gov

20. Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture

    Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatig…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Inova Schar Cancer Institute, Fairfax, Virginia

    Run by

    Inova Health Care Services

    See if you can join NCT07335224 on ClinicalTrials.gov

21. 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

    This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    VA Greater Los Angeles Healthcare System, Los Angeles, California

    Run by

    VA Greater Los Angeles Healthcare System

    See if you can join NCT06706921 on ClinicalTrials.gov

22. HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

    The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully i…

    Stage

    Phase 1

    Ages

    Any age

    Site

    Houston Methodist, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT01913106 on ClinicalTrials.gov